Fibrex, Ikaria Holdings deal

Fibrex granted Ikaria exclusive, worldwide rights to its complete IP portfolio, including the anti-inflammatory fibrin derived peptide FX06 and its two preclinical analogs FX201 and Fx10 7. FX06, which inhibits the binding of fibrin E1 fragment to vascular endothelial (VE) cadherin, is in Phase II testing to prevent ischemia/reperfusion injury following revascularization for acute myocardial infarction (AMI) and in preclinical testing for hemorrhagic shock. FX201 is in development to prevent delayed graft function and for acute lung injury. Fx10 7, a long-acting analog, is in development for sepsis and Dengue fever. Ikaria said it will continue development of the compounds. ...